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Abstract 
BACKGROUND: Psoriasis and inflammatory bowel diseases (IBD) share common pathways based on immune 
dysregulation with an important role of tumour necrosis factor-α and Th17 cells, as well as the genetic 
background. Several studies showed an increased prevalence of psoriasis in IBD patients. However, data 
regarding psoriasis features in IBD patients are still lacking.  
AIM: We aimed to conduct an observational study to assess psoriasis clinical features and its severity in a group 
of patients with IBD. 
METHODS: Dermatological assessment was performed consecutively in 200 IBD patients (123 with CD and 77 
with UC) attending the IBD Care Centre of Gastroenterology at the University of Naples Federico II from 2015 to 
2016. 
RESULTS: A group of 32 from 200 IBD patients (16%) had a familiar history positive for psoriasis, whereas, 
medical history and dermatologic examination revealed that 18 (9%) IBD patients were affected by psoriasis: 11 
out of these 18 subjects (61.2%) had CD, and 7 had UC (38.2%); no significant differences were found between 
CD and UC groups. Concerning psoriasis severity, the mean psoriasis area severity index score was 3.7. 
CONCLUSION: This one-year retrospective study showed that psoriasis and IBD both require the use of 
immunosuppressive drugs so; we can count on a better treatment outcome for both diseases. 
 
 
 
 
 
 
Introduction 
 
Psoriasis and inflammatory bowel diseases 
(IBD), which typically include Crohn’s disease (CD) 
and ulcerative colitis (UC), are chronic relapsing 
inflammatory conditions [1]. Association between 
these diseases is confirmed by a common immune 
dysregulation [increased pro-inflammatory cytokines 
such as tumour necrosis factor (TNF)-α and activated 
Th17 cells] and a shared genetic susceptibility and 
DNA polymorphisms [2], [3], [4]. However, these 
diseases also show some differences, such as the 
efficacy of some agents that highlight discrepancies in 
their pathophysiology [5], [6]. Despite several studies 
report an increased frequency of psoriasis in IBD 
patients, data regarding the clinical features of 
psoriasis in these patients is limited [7], [8]. 
We conducted an observational study to 
assess psoriasis clinical features and its severity in a 
group of patients with IBD. 
 
 
Material and Methods 
 
The dermatological assessment was 
performed consecutively in 200 IBD patients (123 with 
CD and 77 with UC) attending the IBD Care Centre of 
Gastroenterology at the University of Naples Federico 
II from 2015 to 2016. The mean age was 45.7 ± 20.5 
years (ranging from 16 to 77 years), of whom 98 were 
males (49%) and 102 females (51%); the mean 
duration of IBD was 8.7 ± 4.3 years. Almost 30% (n = 
60) of patients were treated with biologic drugs (anti-
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TNF-α such as adalimumab and infliximab) for their 
gastroenterological disease, whereas 70% (n = 140) 
of subjects received conventional therapies (systemic 
steroids, azathioprine, methotrexate and 
aminosalicylates).  
 
 
Results 
 
A group of 32 from 200 IBD patients (16%) 
had a familiar history positive for psoriasis, whereas, 
medical history and dermatologic examination 
revealed that 18 (9%) IBD patients were affected by 
psoriasis: 11 out of these 18 subjects (61.2%) had 
CD, and 7 had UC (38.2%); no significant differences 
were found between CD and UC groups. As regards 
to the 18 patients with both psoriasis and IBD, 8 were 
females and 10 males (mean age 55.3 years, range 
25-75) with a mean IBD duration of 6.7 ± 3.6 years. 
Concerning psoriasis severity, the mean psoriasis 
area severity index score was 3.7. Mild psoriasis was 
more frequent compared to moderate-severe 
psoriasis [16 (88.8%) vs 2 (11.2%); P < 0.01 using 
Student’s t-test] and plaque psoriasis was reported as 
the most common clinical form (n = 17, 94.5%), 
followed by palmoplantar pustular psoriasis (n = 1, 
5.5%). Scalp (9/18; 50.0%), trunk (5/18; 27.7%), 
extensor surfaces of the limbs (5/18; 27.7%) and 
genitals (6/18; 33.3%) represented the sites most 
frequently involved.  
Regarding IBD ongoing treatments, 5/18 
(27.8%) patients received mesalazine, 3/18 (16.7%) 
were on azathioprine therapy, 6/18 (33.3%) received 
adalimumab, and the remaining 4/18 (22.2%) were on 
infliximab treatment. In patients with both IBD and 
psoriasis treated with biologic therapy (10/18, 55.5%) 
the skin disease was not considered a paradoxical 
reaction to biologics since all subjects had already 
shown psoriatic skin lesions before starting anti-TNF-
α, as well as for their clinical aspect. Topical therapies 
based on emollients and low potency corticosteroids 
were able to control psoriatic skin lesions in all 
patients with both IBD and psoriasis. Anti-TNF-α use 
resulted more common in patients with both IBD and 
psoriasis compared to patients with only IBD (55.5% 
vs 30%) probably for the increased level of systemic 
inflammation.  
 
 
Discussion 
 
As reported in previous studies [8], [9], [10], 
the prevalence of psoriasis in IBD patients was three 
times that of the general population (9% vs 3%). 
Furthermore, IBD patients showed a higher frequency 
of mild psoriasis because of the anti-inflammatory and 
immunosuppressive activity of the drugs used for IBD, 
confirming what reported by Eppinga et al., [11]. The 
aetiology of the coexistence of psoriasis and IBD is 
still unknown; the correlation among genetic 
background, immune dysfunction, systemic 
inflammation, and dysregulation of gut microbiota may 
represent possible explanations [12]. It has been 
supposed that this association could be the result of 
the influence of environmental and immunological 
factors, such as IL-17 and TNF- α, in genetically 
predisposed people [11]. Moreover, Lolli et al. 
speculated that some immunological mechanisms 
involved in the pathogenesis of psoriasis (i.e. 
interleukin-23) might play a role in the observed 
different psoriasis phenotypes in the IBD population 
[8].  
Finally, despite the well-known association 
between psoriasis and IBD, our observational study 
showed a very low frequency of moderate and severe 
psoriasis forms in patients with IBD. Further studies 
are needed to highlight eventual peculiarities of 
psoriatic disease in this setting of patients, to set up 
adequate management strategies. 
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